Endometriosis is more than a gynaecological condition.

When I started building in women’s health, I quickly realised something that still surprises me: endometriosis is often treated as a narrow gynaecological issue, while the literature describes something much bigger.

This is not a niche condition.

And yet, for decades, the system has behaved as if the problem was simply that women were not explaining their symptoms clearly enough.

That is not true.

The problem is not a lack of symptoms. The problem is that symptoms are often non-specific, normalised, dismissed, or misattributed. The result is a diagnostic journey that can last years. A recent systematic review found diagnostic delays ranging from 0.3 to 12 years, depending on the study and healthcare setting.

To me, that is not only a clinical problem.

It is a product problem.
It is a data problem.
It is an infrastructure problem.
And, ultimately, it is a failure of imagination.

Why the science matters

I do not believe it is helpful to say that endometriosis is “basically cancer” or “basically an autoimmune disease”. That may sound powerful, but it is not precise enough.

The stronger statement is also the more accurate one:

Endometriosis is its own disease, but it behaves in ways that resemble both.

Recent reviews have mapped endometriosis against the hallmarks of cancer and found evidence across key mechanisms such as abnormal proliferation, immune evasion, invasion, angiogenesis, resistance to apoptosis, and metabolic reprogramming.

At the same time, studies show an association between endometriosis and autoimmune disease. One large case-control study found that women with endometriosis had around twice the odds of receiving at least one autoimmune diagnosis within two years compared with matched controls.

This matters because classification shapes care.

If we keep treating endometriosis as “just painful periods”, we will keep building shallow solutions. If we recognise it as a complex, chronic, systemic condition, then we can start building the kind of infrastructure it actually requires.

The cost is not only medical

From a founder’s point of view, the burden of endometriosis is not only biological. It is operational, economic, emotional, and social.

The literature consistently shows that endometriosis is associated with reduced quality of life, repeated healthcare use, and substantial direct and indirect costs.

Longer diagnostic delays are linked to more emergency visits, more hospitalisations, and higher healthcare costs. Other reviews suggest that indirect costs may represent at least half of the total burden, reflecting lost work time, reduced productivity, and the invisible labour of managing the disease every day.

This is the part people often miss.

A chronic condition is not only symptoms. It is the work of managing symptoms.

It is planning, tracking, explaining, doubting yourself, adapting your day, cancelling things, preparing for pain, and trying to stay functional in a system that rarely captures the full picture.

That hidden work has a cost.

And today, most of that cost is carried by patients.

Why earlier identification matters

Endometriosis is difficult to diagnose partly because symptoms overlap with many other conditions.

Pain.
Fatigue.
Gastrointestinal symptoms.
Urinary symptoms.
Mood changes.
Painful sex.
Bleeding patterns.
Flare-ups.

These signals are often scattered across time, contexts, and specialists.

The healthcare system usually captures snapshots.

But chronic conditions do not happen in snapshots. They happen longitudinally, cyclically, and in real life.

That is where better infrastructure becomes essential.

If a condition has long delays, overlapping symptoms, high healthcare use, and major quality-of-life impact, then the opportunity is not only treatment. The opportunity is earlier identification, better tracking, better patient stratification, and more structured pathways to care.

This is exactly where ENDOless sits.

Why we are building ENDOless

I do not see ENDOless as “another women’s health app”.

That would be too small.

We are building a structured data layer for women’s chronic pain and endometriosis, starting from lived symptoms and translating them into evidence that can be useful for patients, clinicians, researchers, and eventually care systems.

The challenge is not that women do not have data.

Women have years of data in their bodies, calendars, notes, cancelled plans, emergency visits, pain patterns, and unanswered questions.

The challenge is that this data is fragmented, unstructured, and often never reaches the people who could use it to improve care.

ENDOless exists to close that gap.

We adapt research-based questionnaires and clinical logic into a product experience that women can actually use. We help capture symptoms over time, structure the information, and turn lived experience into something more actionable.

This is not about exaggeration. It is about seriousness.

The literature does not support exaggeration.

It supports seriousness.

Endometriosis sits at the intersection of gynaecology, immunology, oncology, chronic pain, and data science. That is part of why it has been so difficult to classify neatly, and part of why it has been underserved for so long.

But difficult does not mean niche.

Complex does not mean impossible.

And women’s pain should not have to become unbearable before the system starts paying attention.

For me, endometriosis is not a “women’s health awareness” story. It is a scientific, clinical, and commercial opportunity to build something the system has been missing for far too long: infrastructure for conditions that live outside the clinic, but shape entire lives.

That is what we are building at ENDOless.

Not because it is easy.

Because the evidence is there.
Because the need is there.
And because women deserve better than being told to wait, explain, and suffer more clearly.